Übersichtsarbeit
HER2-positiv brystkreft
Tidsskrift for Den norske legeforening · 2026
DOI: 10.4045/tidsskr.26.0199 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Tidsskrift for Den norske legeforening, 2026. Verfasst von Kathrine Vandraas und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansFemaleTrastuzumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalMolecular Targeted TherapyAntineoplastic AgentsAntibodies, MonoclonalQuinazolinesLapatinib
Substanzen
Erb-b2 Receptor Tyrosine KinasesTrastuzumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalERBB2 protein, humanAntineoplastic AgentsAntibodies, MonoclonalQuinazolinesLapatinib
Zitieren
APA
Vandraas, K., Naume, B., Sætersdal, A., & Blix, E. (2026). HER2-positiv brystkreft. Tidsskrift for Den norske legeforening. https://doi.org/10.4045/tidsskr.26.0199
Vancouver
Vandraas K, Naume B, Sætersdal A, Blix E. HER2-positiv brystkreft. Tidsskrift for Den norske legeforening. 2026. doi:10.4045/tidsskr.26.0199
BibTeX
@article{Vandraas2026,
author = {Vandraas, Kathrine and Naume, Bjørn and Sætersdal, Anna and Blix, Egil},
title = {HER2-positiv brystkreft},
journal = {Tidsskrift for Den norske legeforening},
year = {2026},
doi = {10.4045/tidsskr.26.0199}
}
EUVIMED